Mechanistic Potential of Taldefgrobep Alfa in Spinal Muscular Atrophy: Lindsey Lee Lair, MD
July 28th 2022The vice president of clinical development at Biohaven shed light on a newly initiated phase 3 study evaluating a promising agent for patients with all types of spinal muscular atrophy. [WATCH TIME: 2 minutes]